|Systematic (IUPAC) name|
|[[Regulation of therapeutic goods |Template:Engvar data]]|
|ATC code||G03XC02 (WHO)|
|Molar mass||470.603 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), under development by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. Pfizer are seeking approval for bazedoxifene in the prevention and treatment of postmenopausal osteoporosis. Bazedoxfiene is the result of an exclusive research collaboration between Wyeth Pharamceuticals and Ligand Pharmaceuticals.
It is approved in the European Union, and is currently in the late phases of review by the United States' Food and Drug Administration. When approved, bazedoxifene is to be sold by Pfizer under the tradename Viviant in the US and Conbriza in the EU. Bazedoxifene's combination with conjugated estrogens, Aprela, is currently undergoing Phase III studies.
History of approval
Wyeth received an approvable letter for bazedoxifene in late April 2007. The FDA called for final safety and efficacy data from Phase III studies, and acceptable valuation of manufacturing and testing facilities where problems were found earlier in the year. Wyeth was working with the FDA to resolve these issues, and expected an FDA action date at the end of 2007.
As of July 2009, the FDA have not given approval for the use of bazedoxifene in the US.
- Biskobing, DM (2007). "Update on bazedoxifene: a novel selective estrogen receptor modulator". Clinical interventions in aging. 2 (3): 299–303. PMC . PMID 18044180.
- "Drugs@FDA - Drug Names Beginning with "B"". Food and Drug Administration. 07 July 2009. Retrieved 2009-07-08. Check date values in:
- "EPARs for authorised medicinal products for human use - Conbriza" (in various). European Medicines Agency. 26 May 2009. Retrieved 2009-07-08.
|This pharmacology-related article is a stub. You can help ssf by expanding it.|